139 related articles for article (PubMed ID: 35739266)
1. Immunophenotypic and molecular characterization of pancreatic neuroendocrine tumors producing serotonin.
Depoilly T; Leroux R; Andrade D; Nicolle R; Dioguardi Burgio M; Marinoni I; Dokmak S; Ruszniewski P; Hentic O; Paradis V; De Mestier L; Perren A; Couvelard A; Cros J
Mod Pathol; 2022 Nov; 35(11):1713-1722. PubMed ID: 35739266
[TBL] [Abstract][Full Text] [Related]
2. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.
Hackeng WM; Brosens LAA; Kim JY; O'Sullivan R; Sung YN; Liu TC; Cao D; Heayn M; Brosnan-Cashman J; An S; Morsink FHM; Heidsma CM; Valk GD; Vriens MR; Nieveen van Dijkum E; Offerhaus GJA; Dreijerink KMA; Zeh H; Zureikat AH; Hogg M; Lee K; Geller D; Marsh JW; Paniccia A; Ongchin M; Pingpank JF; Bahary N; Aijazi M; Brand R; Chennat J; Das R; Fasanella KE; Khalid A; McGrath K; Sarkaria S; Singh H; Slivka A; Nalesnik M; Han X; Nikiforova MN; Lawlor RT; Mafficini A; Rusev B; Corbo V; Luchini C; Bersani S; Pea A; Cingarlini S; Landoni L; Salvia R; Milione M; Milella M; Scarpa A; Hong SM; Heaphy CM; Singhi AD
Gut; 2022 May; 71(5):961-973. PubMed ID: 33849943
[TBL] [Abstract][Full Text] [Related]
3. Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines.
Boora GK; Kanwar R; Kulkarni AA; Pleticha J; Ames M; Schroth G; Beutler AS; Banck MS
Cancer Genet; 2015; 208(7-8):374-81. PubMed ID: 26087898
[TBL] [Abstract][Full Text] [Related]
4. Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?
Luchini C; Lawlor RT; Bersani S; Vicentini C; Paolino G; Mattiolo P; Pea A; Cingarlini S; Milella M; Scarpa A
Curr Oncol Rep; 2021 Jul; 23(9):106. PubMed ID: 34269919
[TBL] [Abstract][Full Text] [Related]
5. Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors.
Thiis-Evensen E; Kjellman M; Knigge U; Gronbaek H; Schalin-Jäntti C; Welin S; Sorbye H; Del Pilar Schneider M; Belusa R;
J Neuroendocrinol; 2022 Jul; 34(7):e13176. PubMed ID: 35829662
[TBL] [Abstract][Full Text] [Related]
6. ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors.
Chou A; Itchins M; de Reuver PR; Arena J; Clarkson A; Sheen A; Sioson L; Cheung V; Perren A; Nahm C; Mittal A; Samra JS; Pajic M; Gill AJ
Hum Pathol; 2018 Dec; 82():249-257. PubMed ID: 30081149
[TBL] [Abstract][Full Text] [Related]
7. Association between preoperative Vasostatin-1 and pathological features of aggressiveness in localized nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET).
Andreasi V; Partelli S; Manzoni M; Muffatti F; Colombo B; Corti A; Falconi M
Pancreatology; 2019 Jan; 19(1):57-63. PubMed ID: 30470614
[TBL] [Abstract][Full Text] [Related]
8. The size of well differentiated pancreatic neuroendocrine tumors correlates with Ki67 proliferative index and is not associated with age.
Partelli S; Muffatti F; Rancoita PMV; Andreasi V; Balzano G; Crippa S; Doglioni C; Rubini C; Zamboni G; Falconi M
Dig Liver Dis; 2019 May; 51(5):735-740. PubMed ID: 30723019
[TBL] [Abstract][Full Text] [Related]
9. Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.
Hackeng WM; Brosens LA; Poruk KE; Noë M; Hosoda W; Poling JS; Rizzo A; Campbell-Thompson M; Atkinson MA; Konukiewitz B; Klöppel G; Heaphy CM; Meeker AK; Wood LD
Hum Pathol; 2016 Oct; 56():93-100. PubMed ID: 27342911
[TBL] [Abstract][Full Text] [Related]
10. Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2.
Hermann G; Konukiewitz B; Schmitt A; Perren A; Klöppel G
Virchows Arch; 2011 Aug; 459(2):147-54. PubMed ID: 21739268
[TBL] [Abstract][Full Text] [Related]
11. Serotonin, ATRX, and DAXX Expression in Pituitary Adenomas: Markers in the Differential Diagnosis of Neuroendocrine Tumors of the Sellar Region.
Casar-Borota O; Botling J; Granberg D; Stigare J; Wikström J; Boldt HB; Kristensen BW; Pontén F; Trouillas J
Am J Surg Pathol; 2017 Sep; 41(9):1238-1246. PubMed ID: 28719461
[TBL] [Abstract][Full Text] [Related]
12. Rb and p53 Execute Distinct Roles in the Development of Pancreatic Neuroendocrine Tumors.
Yamauchi Y; Kodama Y; Shiokawa M; Kakiuchi N; Marui S; Kuwada T; Sogabe Y; Tomono T; Mima A; Morita T; Matsumori T; Ueda T; Tsuda M; Nishikawa Y; Kuriyama K; Sakuma Y; Ota Y; Maruno T; Uza N; Masuda A; Tatsuoka H; Yabe D; Minamiguchi S; Masui T; Inagaki N; Uemoto S; Chiba T; Seno H
Cancer Res; 2020 Sep; 80(17):3620-3630. PubMed ID: 32591410
[TBL] [Abstract][Full Text] [Related]
13. RSUME is implicated in tumorigenesis and metastasis of pancreatic neuroendocrine tumors.
Wu Y; Tedesco L; Lucia K; Schlitter AM; Garcia JM; Esposito I; Auernhammer CJ; Theodoropoulou M; Arzt E; Renner U; Stalla GK
Oncotarget; 2016 Sep; 7(36):57878-57893. PubMed ID: 27506944
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of OTP and NKX6.1 in neuroendocrine tumors of the lung and pancreas.
Yoxtheimer LM; Heymann JJ; Cohen C; Rao RA; Goyal A; Siddiqui MT
Diagn Cytopathol; 2018 Dec; 46(12):1010-1014. PubMed ID: 30284410
[TBL] [Abstract][Full Text] [Related]
15. EUS-guided FNA cytology of pancreatic neuroendocrine tumour (PanNET): a retrospective study of 132 cases over an 18-year period in a single institution.
Chen S; Lin J; Wang X; Wu HH; Cramer H
Cytopathology; 2014 Dec; 25(6):396-403. PubMed ID: 24635775
[TBL] [Abstract][Full Text] [Related]
16. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
17. Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours.
Mohanty SK; Tiwari A; Bhardwaj N; Chuang F; Kim E; Lugo H; Yuan X; Diffalha SA; Peralta-Venturina M; Balzer B; Dhall D
J Clin Pathol; 2021 Sep; 74(9):582-588. PubMed ID: 32934105
[TBL] [Abstract][Full Text] [Related]
18. Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression.
Martin DR; LaBauve E; Pomo JM; Chiu VK; Hanson JA; Gullapalli RR
Pancreas; 2018 Apr; 47(4):502-510. PubMed ID: 29521944
[TBL] [Abstract][Full Text] [Related]
19. [Practical application of immunohistochemistry in pancreatic neuroendocrine neoplasms : Tips and pitfalls].
Bräutigam K; Chouchane A; Konukiewitz B; Perren A
Pathologie (Heidelb); 2024 Feb; 45(1):35-41. PubMed ID: 38175232
[TBL] [Abstract][Full Text] [Related]
20. Is the Real Prevalence of Pancreatic Neuroendocrine Tumors Underestimated? A Retrospective Study on a Large Series of Pancreatic Specimens.
Partelli S; Giannone F; Schiavo Lena M; Muffatti F; Andreasi V; Crippa S; Tamburrino D; Zamboni G; Rubini C; Doglioni C; Falconi M
Neuroendocrinology; 2019; 109(2):165-170. PubMed ID: 31117106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
